Measuring Lactation Initiation After Early Postpartum Injectable Progestin (DMPA) Use Among Women in Dhanusha District of Nepal: A Pilot Study
Launched by UNIVERSITY OF CALIFORNIA, SAN DIEGO · Feb 4, 2025
Trial Information
Current as of July 06, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the use of a contraceptive injection called depo medroxyprogesterone acetate (DMPA) shortly after giving birth. The study will involve 40 women in the Dhanusha District of Nepal who have recently had a baby. Researchers want to see if starting DMPA soon after delivery affects how well mothers can start breastfeeding and how their babies grow. This pilot study is an early step to see if a larger study can be done in the future.
To be eligible for this trial, women must live in Nepal, have given birth to a single healthy baby within the last 48 hours, and not have started producing milk yet. They should also want to use DMPA for contraception after giving birth. However, women who want to get pregnant again in less than six months, do not plan to exclusively breastfeed for six months, or have certain medical conditions will not be able to participate. If they join the study, participants can expect support and monitoring regarding their use of DMPA and breastfeeding.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Currently live in Nepal
- • Had a vaginal or cesarean delivery of a singleton full-term infant within the past 48 hours
- • Not yet undergone lactogenesis
- • Desire to use DMPA as a method of postpartum contraception
- Exclusion Criteria:
- • Desire a repeat pregnancy in less than 6 months
- • Do not intend to exclusively feed infant own human milk for 6 months
- • Do not have access to a telephone
- • Any medical contraindication to DMPA
- • Any contraindication to human milk feeding for their infant
- • History of breast surgery (augmentation or reduction)
- • Infant with a major congenital anomaly (will be excluded due to unique challenges with feeding in these populations)
About University Of California, San Diego
The University of California, San Diego (UCSD) is a leading academic institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. With a robust focus on translational medicine, UCSD leverages its interdisciplinary approach to explore groundbreaking therapies and interventions across a wide range of medical fields. The university's state-of-the-art facilities and collaboration with top-tier faculty and researchers ensure a comprehensive and ethical framework for conducting clinical trials, ultimately aiming to enhance patient outcomes and contribute to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Janakpur, Dhanusha District, Nepal
Patients applied
Trial Officials
Sarah Averbach, MD, MAS
Principal Investigator
University of California, San Diego
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported